Effects of amyloid precursor protein peptide APP96-110,alone or with human mesenchymal stromal cells,on recovery after spinal cord injury  

在线阅读下载全文

作  者:Stuart I.Hodgetts Sarah J.Lovett D.Baron-Heeris A.Fogliani Marian Sturm C.Van den Heuvel Alan R.Harvey 

机构地区:[1]School of Human Sciences,The University of Western Australia(UWA),Perth,WA,Australia [2]Perron Institute for Neurological and Translational Science,Perth,WA,Australia [3]Cell and Tissue Therapies WA(CTTWA),Royal Perth Hospital,Perth,WA,Australia [4]Adelaide Medical School,Faculty of Health and Medical Sciences,The University of Adelaide,Adelaide,SA,Australia

出  处:《Neural Regeneration Research》2022年第6期1376-1386,共11页中国神经再生研究(英文版)

基  金:the Neurotrauma Research Program of Western Australia.

摘  要:Delivery of a peptide(APP96-110),derived from amyloid precursor protein(APP),has been shown to elicit neuroprotective effects following cerebral stroke and traumatic brain injury.In this study,the effect of APP96-110 or a mutant version of this peptide(mAPP96-110)was assessed following moderate(200 kdyn,(2 N))thoracic contusive spinal cord injury(SCI)in adult Nude rats.Animals received a single tail vein injection of APP96-110 or mAPP96-110 at 30 minutes post-SCI and were then assessed for functional improvements over the next 8 weeks.A cohort of animals also received transplants of either viable or non-viable human mesenchymal stromal cells(hMSCs)into the SC lesion site at one week post-injury to assess the effect of combining intravenous APP96-110 delivery with hMSC treatment.Rats were perfused 8 weeks post-SCI and longitudinal sections of spinal cord analyzed for a number of factors including hMSC viability,cyst size,axonal regrowth,glial reactivity and macrophage activation.Analysis of sensorimotor function revealed occasional significant differences between groups using Ladderwalk or Ratwalk tests,however there were no consistent improvements in functional outcome after any of the treatments.mAPP96-110 alone,and APP96-110 in combination with both viable and non-viable hMSCs significantly reduced cyst size compared to SCI alone.Combined treatments with donor hMSCs also significantly increased βIII tubulin^(+),glial fibrillary acidic protein(GFAP^(+))and laminin+expression,and decreased ED1^(+)expression in tissues.This preliminary study demonstrates that intravenous delivery of APP96-110 peptide has selective,modest neuroprotective effects following SCI,which may be enhanced when combined with hMSC transplantation.However,the effects are less pronounced and less consistent compared to the protective morphological and cognitive impact that this same peptide has on neuronal survival and behaviour after stroke and traumatic brain injury.Thus while the efficacy of a particular therapeutic approach in one CNS inj

关 键 词:amyloid precursor protein cell transplantation combination CONTUSION functional recovery mesenchymal stromal cells NEUROPROTECTION REGENERATION spinal cord injury tissue sparing 

分 类 号:R453[医药卫生—治疗学] R364[医药卫生—临床医学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象